Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities

Shi Wei Chao, Liang Chieh Chen, Chia Chun Yu, Chang Yi Liu, Tony Eight Lin, Jih Hwa Guh, Chen Yu Wang, Chun Yung Chen, Kai Cheng Hsu, Wei Jan Huang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) is a validated drug target for various diseases. This study combined indole recognition cap with SAHA, an FDA-approved HDAC inhibitor used to treat cutaneous T-cell lymphoma (CTCL). The structure activity relationship of the resulting compounds that inhibited HDAC was disclosed as well. Some compounds exhibited much stronger inhibitory activities than SAHA. We identified two meta-series compounds 6j and 6k with a two-carbon linker had IC50 values of 3.9 and 4.5 nM for HDAC1, respectively. In contrast, the same oriented compounds with longer carbon chain linkers showed weaker inhibition. The result suggests that the linker chain length greatly contributed to enzyme inhibitory potency. In addition, comparison of enzyme-inhibiting activity between the compounds and SAHA showed that compounds 6j and 6k displayed higher inhibiting activity for class I (HDAC1, -2, -3 and -8). The molecular docking and structure analysis revealed structural differences with the inhibitor cap and metal-binding regions between the HDAC isozymes that affect interactions with the inhibitors and play a key role for selectivity. Further biological evaluation showed multiple cellular effects associated with compounds 6j- and 6k-induced HDAC inhibitory activity.

Original languageEnglish
Pages (from-to)792-805
Number of pages14
JournalEuropean Journal of Medicinal Chemistry
Volume143
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Histone Deacetylases
Derivatives
Carbon
Molecular Docking Simulation
Cutaneous T-Cell Lymphoma
Histone Deacetylase Inhibitors
T-cells
Enzyme activity
Enzymes
Structure-Activity Relationship
Molecular Structure
Chain length
Structural analysis
Isoenzymes
Inhibitory Concentration 50
Metals
indole
Pharmaceutical Preparations

Keywords

  • Histone deacetylase
  • Indole
  • Isozyme
  • Molecular docking
  • Structure activity relationship

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities. / Chao, Shi Wei; Chen, Liang Chieh; Yu, Chia Chun; Liu, Chang Yi; Lin, Tony Eight; Guh, Jih Hwa; Wang, Chen Yu; Chen, Chun Yung; Hsu, Kai Cheng; Huang, Wei Jan.

In: European Journal of Medicinal Chemistry, Vol. 143, 01.01.2018, p. 792-805.

Research output: Contribution to journalArticle

Chao, Shi Wei ; Chen, Liang Chieh ; Yu, Chia Chun ; Liu, Chang Yi ; Lin, Tony Eight ; Guh, Jih Hwa ; Wang, Chen Yu ; Chen, Chun Yung ; Hsu, Kai Cheng ; Huang, Wei Jan. / Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities. In: European Journal of Medicinal Chemistry. 2018 ; Vol. 143. pp. 792-805.
@article{eb5217500ccf454285ad1a5a119f7fe6,
title = "Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities",
abstract = "Histone deacetylase (HDAC) is a validated drug target for various diseases. This study combined indole recognition cap with SAHA, an FDA-approved HDAC inhibitor used to treat cutaneous T-cell lymphoma (CTCL). The structure activity relationship of the resulting compounds that inhibited HDAC was disclosed as well. Some compounds exhibited much stronger inhibitory activities than SAHA. We identified two meta-series compounds 6j and 6k with a two-carbon linker had IC50 values of 3.9 and 4.5 nM for HDAC1, respectively. In contrast, the same oriented compounds with longer carbon chain linkers showed weaker inhibition. The result suggests that the linker chain length greatly contributed to enzyme inhibitory potency. In addition, comparison of enzyme-inhibiting activity between the compounds and SAHA showed that compounds 6j and 6k displayed higher inhibiting activity for class I (HDAC1, -2, -3 and -8). The molecular docking and structure analysis revealed structural differences with the inhibitor cap and metal-binding regions between the HDAC isozymes that affect interactions with the inhibitors and play a key role for selectivity. Further biological evaluation showed multiple cellular effects associated with compounds 6j- and 6k-induced HDAC inhibitory activity.",
keywords = "Histone deacetylase, Indole, Isozyme, Molecular docking, Structure activity relationship",
author = "Chao, {Shi Wei} and Chen, {Liang Chieh} and Yu, {Chia Chun} and Liu, {Chang Yi} and Lin, {Tony Eight} and Guh, {Jih Hwa} and Wang, {Chen Yu} and Chen, {Chun Yung} and Hsu, {Kai Cheng} and Huang, {Wei Jan}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ejmech.2017.11.092",
language = "English",
volume = "143",
pages = "792--805",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities

AU - Chao, Shi Wei

AU - Chen, Liang Chieh

AU - Yu, Chia Chun

AU - Liu, Chang Yi

AU - Lin, Tony Eight

AU - Guh, Jih Hwa

AU - Wang, Chen Yu

AU - Chen, Chun Yung

AU - Hsu, Kai Cheng

AU - Huang, Wei Jan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Histone deacetylase (HDAC) is a validated drug target for various diseases. This study combined indole recognition cap with SAHA, an FDA-approved HDAC inhibitor used to treat cutaneous T-cell lymphoma (CTCL). The structure activity relationship of the resulting compounds that inhibited HDAC was disclosed as well. Some compounds exhibited much stronger inhibitory activities than SAHA. We identified two meta-series compounds 6j and 6k with a two-carbon linker had IC50 values of 3.9 and 4.5 nM for HDAC1, respectively. In contrast, the same oriented compounds with longer carbon chain linkers showed weaker inhibition. The result suggests that the linker chain length greatly contributed to enzyme inhibitory potency. In addition, comparison of enzyme-inhibiting activity between the compounds and SAHA showed that compounds 6j and 6k displayed higher inhibiting activity for class I (HDAC1, -2, -3 and -8). The molecular docking and structure analysis revealed structural differences with the inhibitor cap and metal-binding regions between the HDAC isozymes that affect interactions with the inhibitors and play a key role for selectivity. Further biological evaluation showed multiple cellular effects associated with compounds 6j- and 6k-induced HDAC inhibitory activity.

AB - Histone deacetylase (HDAC) is a validated drug target for various diseases. This study combined indole recognition cap with SAHA, an FDA-approved HDAC inhibitor used to treat cutaneous T-cell lymphoma (CTCL). The structure activity relationship of the resulting compounds that inhibited HDAC was disclosed as well. Some compounds exhibited much stronger inhibitory activities than SAHA. We identified two meta-series compounds 6j and 6k with a two-carbon linker had IC50 values of 3.9 and 4.5 nM for HDAC1, respectively. In contrast, the same oriented compounds with longer carbon chain linkers showed weaker inhibition. The result suggests that the linker chain length greatly contributed to enzyme inhibitory potency. In addition, comparison of enzyme-inhibiting activity between the compounds and SAHA showed that compounds 6j and 6k displayed higher inhibiting activity for class I (HDAC1, -2, -3 and -8). The molecular docking and structure analysis revealed structural differences with the inhibitor cap and metal-binding regions between the HDAC isozymes that affect interactions with the inhibitors and play a key role for selectivity. Further biological evaluation showed multiple cellular effects associated with compounds 6j- and 6k-induced HDAC inhibitory activity.

KW - Histone deacetylase

KW - Indole

KW - Isozyme

KW - Molecular docking

KW - Structure activity relationship

UR - http://www.scopus.com/inward/record.url?scp=85036670008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036670008&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2017.11.092

DO - 10.1016/j.ejmech.2017.11.092

M3 - Article

C2 - 29223096

AN - SCOPUS:85036670008

VL - 143

SP - 792

EP - 805

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -